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Abstract 
The formulation of three phytopharmaceutical products of Andrographispaniculata fractions (AP fraction A and B) containing 
diterpene lactones as an active substance were developed and their antimalarial activities against Plasmodium bergheihas been 
examined. In vivo antimalarial assay on P. berghei infected mice was carried out by oral administration,twice a dayfor four 
consecutive days of the AP fractions product, which were Tablet I : wet granulated formula of AP fraction A; Tablet II : wet 
granulated formula of AP fraction B; Tablet III : solid dispersion formula of AP fraction B.. The results revealed that three 
phytopharmaceutical products of A.paniculata were inhibited parasite’s growth with inhibition range of 70.15% to 80.35%. There 
was no significant difference of antimalarial activities between Tablet II and III, meanwhile there was significant difference 
among Tablet I with Tablet II and Tablet III.It was concluded that antimalarial activity depending on raw material form of A. 
paniculata active substance. 
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1. Introduction 
Malaria was one of the oldest recorded diseases in the world. Each year from 300 to 500 million new cases were 
diagnosed and approximately 1.5 million people diedbecause the disease; majority were children1. The re-emerging 
of malaria in many parts of the world was due to the rapid increasing of resistance to most of the available 
antimalarial drugs, as well as resistance of vectors to insecticides2,3. Drug resistant for strains of Plasmodium. 
falciparum has been found in many endemic areas of the world and many of conventional anti-malarial drugs have 
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been associated with treatment failure. Furthermore, the difficulty of creating efficient vaccines and also adverse 
side-effects of the existing antimalarial drugs highlight the urgent need for novel and well-tolerated antimalarial 
drugs2 for both prophylaxis and treatment of malaria. 
Andrographis paniculata Nees which known as sambiloto was traditionally used for antimalaria in Indonesia. 
The previous research had shown that A. paniculata extract have antimalarial activity both in vitro and in vivo4,5. 
Methanol extract of A. paniculata exhibited antimalarial activity against P. falciparum with IC50 value of 7.2 μg/ml. 
Futhermore, the results of in vivo toxicity assay indicating no toxicity associated with the use of this extract in mice 
system5. Andrographolide was the main content of sambiloto which reported have antimalarial activity. 
Andrographolide has IC50 value of 9.1 μM6. Andrographolide was considered to be active compound and has good 
antimalarial activity based on its IC50 value which was less than 20 μM7. Our previous research also found that 
andrographolide shown antiplasmodial activity as blood schizontocidal activity and also gametocytocidal  with IC50 
value of 12.16 and 3.61 μg/ml, respectively8.   
Regarding to the potential antimalarial activity of A. paniculata, Widyawaruyanti et al9 was developed 
phytopharmaceutical products by conducted formulation study of two fractions from ethanol extract of this plant 
which were AP fraction A and B. AP fraction A was obtained from fractionated ethanol extract using ethyl acetate, 
while further purification of AP fraction A resulted as AP fraction B. Although AP fractions have different 
physicochemical properties, both of them were contain andrographolide (diterpene lactone compound) as an active 
substance. The formulation study of AP fractions A and B was performed based on two methods which were wet 
granulation and solid dispersion, therefore three phytopharmaceutical products were obtained which were Tablet I: 
wet granulated formula of AP fraction A; Tablet II: wet granulated formula of AP fraction B; and Tablet III: solid 
dispersion formula of AP fraction B. 
The aim of this study was to observe in vivo antimalarial activities of Tablet I, II and III based on The Peter’s test 
(The 4-days suppressive test) by oral administration of products at a dose of 12.55 mg andrographolide/kg mice 
body weight, twice a day for four consecutive days.. 
2. Experiments 
2.1. Material 
A. paniculata dry herbs powder was obtained from pharmaceutical company PT. Kimia Farma Tbk, Bandung, 
Indonesia. A. paniculata was extracted by maceration method using ethanol 96% as a solvent. Ethanol extract of A. 
paniculatawas further fractionated by liquid-liquid fractionation method using ethyl acetate and water to obtain AP 
fraction A. Dried AP fraction A was further purified so that AP fraction B was obtained. AP fraction A was dark 
green and sticky, meanwhile AP fraction B was greenish amorphous powder. 
Tablet I contained of 75 mg of  AP fraction A per 400 mg tabletformulated by wet granulation  method. Tablet II 
contained of 15 mg of  AP fraction B per 300 mg tabletformulated by wet granulation method. Tablet  III contained 
of  60 mg of AP fraction B per 150 mg tablet  formulated  by  solid dispersion method.  
The chloroquine sensitive Plasmodium berghei ANKA strain was obtained from Institute of Biomolecular 
Eijkmann, Jakarta and maintained on mice at Malaria Laboratorium, Faculty of Pharmacy, Universitas Airlangga. 
The inoculum of P. berghei parasitized erythrocytes was prepared by determining the percentage parasitemia of 
mice donor and diluting the blood with alceivers solutions in proportion indicated by the determination. The mice 
were infected intraperitonially with 200 μL of 5% parasite blood stock from frozen deposits. Once the percent of 
parasitemiaon this donor mice reached 20%, the mice blood taken intracardially and diluted with PBS or alceivers 
solutions (1:3) up to 5% parasitemia. The test mice has been infected by 200 μL of this diluted parasitized blood that 
contain 5% parasite. 
Male albino Swiss mice Balb-C strain (20-30 g weight) were obtained from Animal Laboratory, Faculty of  
Pharmacy, Universitas Airlangga. They were maintained on standard animal pellets and water ad libitum. 
Permission and approval for animal studies were obtained from Faculty of Veterinary Medicine, Universitas 
Airlangga. 
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2.2. Methods 
2.2.1. Preparation of samples 
Tablet I, Tablet II and Tablet IIIof which were equal to 12.55mg andrographolide/kg mice body weight were 
powdered and suspended in 0.5% CMCNa solution. Sample solutions were administered per oral (1 ml/mouse) 
twice a day. 
2.2.2. In vivo antimalarial assay  
Antimalarial activity of Tablet I, II and IIIwere evaluated using the Peter’s test methods  (The 4-days suppressive 
test). Each mouse was inoculated intraperitoneally on the first day (day 0) with 0.2 ml of infected blood containing 
P. berghei parasitized erythrocytes (5% parasitemia). The animals were divided into four  groups of five mice each 
and administered orally with  suspension of Tablet I, Tablet II and Tablet III containing andrographolide 12.55 
mg/kg body weight twice a day and an equivalent volume of CMC-Na solutions  (as negative control) at one day  
after  inoculation, for four consecutive days (day 0 to day 3). On the fifth day (day 4), thin films were made from the 
tail blood of each mouse and the parasitemia level was determined by counting the number of parasitized 
erythrocytes out of 1000 erythrocytes in random fields of the microscope. Average percentage parasite’s inhibition 
was calculated as following: 
 
Xe: % parasitemia growth of experimental group 
Xk: % parasitemia growth of negative control 
3. Results and Discussion 
Tablet I, II and III produced inhibition effect at a dose employed in this study. The parasite’s inhibition were 
70.35%, 78.16% and 80.35% for sample equal to andrographolide 20.10 mg/kg/day dose of Tablet I, II and III 
respectively. The inhibition produced by the products were significant (P< 0.05) compared to control (Table 1). 
Tabel 1.AntiplasmodialActiviry of Tablet I, II, and III during 4-days Test 





Average  inhibition 
(%) 
Tablet I AP fraction A 25.10 3.37±0.29 70.15 
Tablet II AP fraction B 25.10 2.85±0.48 78.16 
Tablet III AP fraction B 25.10 2.96±0.41 80.35 
Negative control - - 10.85±1.54 - 
Data were expressed as mean±SD for five animals per group F=53.789 
*P<0.001 compared to control 
 
The data was analyzed by one-way analysis of variance (one way ANOVA) at 95% confidence limit (α =0.05) to 
detect the significant differences ininhibition of parasite’s growth of each test group. ANOVA and Post Hoc LSD 
(Least Significant Difference) test resulted the calculating F(53.789) and P <(0.001). It concluded that there were 
significant difference among Tablet I and Tablet II, Tablet I and Tablet III, but no significant difference between 
Tablet II and Tablet III.  Tablet I and II displayed different antimalarial activity, they were formulated by the same 
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method, but different in active substance. Meanwhile, Tablet II and Tablet III displayed similar antimalarial activity, 
in which they were formulated by different method but contain the same active substance. 
The antimalarial activities of Tablet I, II and III were mainly due to the active substances which contained in 
tablets instead of formulation method which conducted to produce tablets. Regarding to the fact that 
andrographolide was one of the active substances which proven active as an antimalarial and assumed to be 
responsible to the antimalarial activity of A. paniculata, then tablets were produced based on the content of 
andrographolide. Tablet I, II and III were containing the same andrographolide level as an effort to reach the same 
antimalarial activity level. Tablet I contain AP fraction A which was crude ethyl acetate fraction of A. paniculata 
extract with multi-components content and lower concentration of andrographolide, meanwhile tablet II and III 
contain AP fraction B which was diterpene lactone fraction obtained from purification of AP fraction A, more 
concentrate with higher andrographolide concentration. AP fraction B has shown better antimalarial activity than AP 
fraction A at the same level of andrographolide.  Physicochemical properties of AP fraction B was greenish 
amorphous powder shown different form with AP fraction A which was dark green and sticky. There was a 
possibility that the sticky form of AP fraction A affected the dissolution profile of andrographolide as an active 
substance and produced the low bioavailability in the in vivo system. The results shown that the form of raw 
material of A. paniculata fractions were influenced the antimalarial activities of tablets. 
4. Conclusion 
A. paniculata formulated products containing AP fraction B as an active substance in Tablet II and III showed 
higher parasite growth’s inhibition than product containing AP fraction A in Tablet I. The different formulation 
method was not influenced the antimalarial activity. The antimalarial activity productsdepending on the raw material 
form of A. paniculata fraction which contained in the products. 
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